Spero Therapeutics, Inc. (SPRO) financial statements and ratios from SEC XBRL: revenue $66.80M (TTM), net margin 12.8%, revenue growth -100.0% YoY, P/E 9.6. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $66.80M |
| Net Margin | 12.8% |
| Revenue Growth (YoY) | -100.0% |
| EPS Growth (YoY) | 433.3% |
| P/E Ratio | 9.6 |
| EV / EBITDA | 3.3 |
| Price / Book | 1.60 |
| Price / Sales | 1.51 |
| Altman Z-Score | -2.58 (distress) |
| Sector P/E (Healthcare) | 21.7 |
SPRO overview · SPRO earnings · SPRO KPIs · SPRO investor relations · SPRO ownership · SPRO peers · SPRO filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.